Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Veren Inc. (VRN) Stock Forecast & Price Prediction Canada | NYSE | Energy | Oil & Gas E&P
$6.01
+0.00 (0.00%)Did VRN Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Veren is one of their latest high-conviction picks.
VRN has shown a year-to-date change of 0.0% and a 1-year change of 0.0%, reflecting flat performance over the past year. Comprehensive analyst forecasts are currently unavailable for VRN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for VRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 1, 2024 | RBC Capital | Michael Harvey | Outperform | Maintains | $10.00 |
| Oct 18, 2024 | Raymond James | Luke Davis | Strong Buy | Initiates | $13.00 |
| Jul 12, 2024 | Scotiabank | Sector Outperform | Maintains | $15.00 |
The following stocks are similar to Veren based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Veren Inc. has a market capitalization of $3.69B with a P/E ratio of 18.2x. The company generates $2.91B in trailing twelve-month revenue with a 6.9% profit margin.
Revenue growth is +5.6% quarter-over-quarter, while maintaining an operating margin of +15.1% and return on equity of +4.2%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Develops innovative therapies for unmet medical needs.
Veren Inc. generates revenue through the discovery and development of biotechnology solutions, focusing on therapies for rare and complex diseases. The company partners with academic institutions and pharmaceutical firms to enhance its research capabilities and expedite the drug development process, which can lead to licensing agreements and commercialization once therapies are approved.
Veren Inc. is located in a major biotech hub, positioning itself strategically within the industry. Its strong pipeline of drug candidates and commitment to advanced research contribute to its influence in the biotechnology sector, attracting investor interest in healthcare innovations.
Energy
Oil & Gas E&P
746
Mr. Craig Bryksa
Canada
2003
Whitecap Resources Inc. will acquire Veren Inc. in a business combination approved by the Court of King's Bench of Alberta, with Veren shareholders receiving 1.05 Whitecap shares for each Veren share.
The court's approval of Whitecap's acquisition of Veren enhances Whitecap's market position and may impact stock values, investor sentiment, and future growth potential for both companies.
Wall Street analysts suggest a 35% potential upside for Veren (VRN), supported by positive earnings estimate revisions, despite questions about the reliability of price targets.
A 35% potential upside in price targets suggests strong growth prospects for Veren (VRN), while rising earnings estimates could further boost investor confidence and stock value.
Veren (VRN) is expected to report strong earnings, having the right factors for a likely earnings beat in its upcoming report.
Veren's potential for an earnings beat could drive stock prices up, signaling strong performance and attracting investor interest. Positive earnings reports often boost market confidence.
An investor sold oil stocks to acquire a large position in Whitecap Resources, citing strong Q1 results, a beneficial merger, and a sustainable 9% dividend yield with reduced breakeven costs.
The shift from oil stocks to Whitecap Resources highlights confidence in merger synergies, strong production, and sustainable dividends, signaling potential growth and resilience in a volatile market.
Investors are advised to monitor three dividend stocks for 2025: SLB, IMO, and VRN.
Potential for steady income in 2025 from SLB, IMO, and VRN could attract income-focused investors, impacting demand and stock prices.
Wall Street analysts' average price target for Veren (VRN) suggests a potential upside of 27.6%. Positive earnings estimate revisions may support this growth.
The 27.6% potential upside suggests strong growth prospects for Veren (VRN), and positive earnings revisions could further boost investor confidence and stock performance.
Analyst forecasts for Veren Inc. (VRN) are not currently available. The stock is trading at $6.01.
According to current analyst ratings, VRN has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.01. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for VRN are not currently available. The stock is trading at $6.01.
Veren Inc. generates revenue through the discovery and development of biotechnology solutions, focusing on therapies for rare and complex diseases. The company partners with academic institutions and pharmaceutical firms to enhance its research capabilities and expedite the drug development process, which can lead to licensing agreements and commercialization once therapies are approved.
Price targets from Wall Street analysts for VRN are not currently available. The stock is trading at $6.01.
Price targets from Wall Street analysts for VRN are not currently available. The stock is trading at $6.01.
The overall analyst consensus for VRN is bullish. Out of 3 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell.
Stock price projections, including those for Veren Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.